Advantech Unveils AFE-R360: A Next-Generation AMR Solution with MIPI-CSI & GMSL Camera Integration Powered by Intel® Core™ Ultra
TAIPEI, Oct. 31, 2024 /PRNewswire/ — Advantech (TWSE: 2395), a global leader in AIoT and Edge Computing, is thrilled to introduce the AFE-R360. The AFE-R360... Read more.
Global Times: Species thriving thanks to policy, consensus in China
BEIJING, Oct. 31, 2024 /PRNewswire/ — Under the global framework for biodiversity, more wildlife species are increasing in number and enjoying a better space... Read more.
Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combination as First-Line Therapy for Biliary Tract Tumors, Compared to Durvalumab
HONG KONG, Oct. 31, 2024 /PRNewswire/ — Akeso Biopharma (9926.HK) is pleased to announce the successful enrollment of the first patient in the HARMONi-GI-01/AK112-309... Read more.
CARsgen® U.S. Clinical Holds Lifted by FDA
SHANGHAI, Oct. 31, 2024 /PRNewswire/ — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for... Read more.
DermRays Set to Launch New Men’s Hair Removal Device Summer 2025
PLEASANTON, Calif., Oct. 31, 2024 /PRNewswire/ — DermRays is excited to announce a groundbreaking addition to its product line aimed specifically at male users.... Read more.
ESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
Efficacy signals observed will not achieve ESSA’s target product profile in patients with metastatic castration-resistant prostate cancer naïve to second-generation... Read more.
Eisai completes rolling BLA submission for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US
STOCKHOLM, Oct. 31, 2024 /PRNewswire/ — BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Eisai has completed the rolling... Read more.
Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million
VICTORIA, BC, Oct. 31, 2024 /PRNewswire/ – Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX: EPRX) (NASDAQ: EPRX),... Read more.
Robert Half Honored by Fortune and Forbes for Empowering Women in the Workplace
MENLO PARK, Calif., Oct. 31, 2024 /PRNewswire/ — Global talent solutions and business consulting firm Robert Half (NYSE: RHI) has been named one of Fortune’s... Read more.
Nektar to Announce Financial Results for the Third Quarter 2024 on Thursday, November 7, 2024, After Close of U.S.-Based Financial Markets
SAN FRANCISCO, Oct. 31, 2024 /PRNewswire/ — Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2024 on Thursday,... Read more.